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Introduction
The transforming growth factor (TGF) βs are polypeptides with-
in a superfamily of ligands that includes the TGFβs, activins,
and bone morphogenetic proteins (BMPs).TGFβ ligands play a
role in cell proliferation, functional differentiation, extracellular
matrix (ECM) production, cell motility, and apoptosis
(Massagué, 1998). Three mammalian TGFβ isoforms, TGFβ1,
TGFβ2, and TGFβ3, have been identified. In general, they
exhibit similar functions in vitro, most notably on cell growth
regulation, ECM production, and immune modulation.
However, each appears to have distinct activities in vivo, as evi-
denced by the distinct phenotypes of mice lacking any one of
the TGFβ ligands (Massagué, 1998). The TGFβs bind to a het-
eromeric complex of transmembrane serine/threonine kinases,
the type I and type II receptors (TβRI and TβRII). Following lig-
and binding to TβRII, TβRI is recruited to the complex. This
allows for the constitutively active TβRII kinase to transphos-
phorylate and activate the TβRI kinase which, in turn, phospho-
rylates Smad2 and Smad3. Smad2/3 then associate with a
common mediator Smad, Smad4, and translocate to the nucle-
us, where they regulate gene transcription. By contrast, the
inhibitory Smad7 can interact with TβRI and prevent the phos-
phorylation of the effectors Smad2/3 (Massagué et al., 2000).
In addition to Smads, more recently, other signaling pathways
have been implicated in TGFβ actions. These include the extra-
cellular signal-regulated kinase (ERK), c-Jun NH2-terminal
kinase (JNK), p38 mitogen-activated protein kinase (MAPK),
phosphatidylinositol-3 kinase (PI3K), and Rho GTPases
(reviewed in Derynck et al., 2001).
TGFβ is both a tumor suppressor and a tumor promoter
The ability of TGFβ to inhibit epithelial cell proliferation suggests
a role in tumor suppression. MMTV/TGFβ1S223/225 transgenic
mice expressing active TGFβ1 in the mammary gland exhibit a
hypoplastic ductal epithelium (Pierce et al., 1993). Conversely,
expression of dominant negative TβRII results in accelerated
lobulo-alveolar mammary development (Gorska et al., 1998)
and enhanced propensity for carcinogen-induced lung, mam-
mary, and skin tumors (Bottinger et al., 1997). Mice with target-
ed disruption of either the Tgfb1 or the Smad3 gene develop
colon adenomas and carcinomas (Engle et al., 1999; Zhu et al.,
1998). Mice carrying an inactivated allele of Smad4 develop
intestinal polyps that progress to carcinomas (Xu et al., 2000).
Finally, mice heterozygous for the Tgfb1 gene express
10%–30% of the TGFβ1 protein, and this partial loss results in
enhanced carcinogen-induced tumors (Tang et al., 1998).
TGFβ function is also compromised in some human can-
cers. Mutations in the TGFBR2 gene occur in both sporadic
and inherited colon cancers with microsatellite instability, and
reconstitution of TβRII expression reverses transformation in
colon cancer cell lines (Markowitz et al., 1995). Inactivating
mutations in genes encoding Smad2 and Smad4 have been
found in cancers of the gastrointestinal tract and pancreas
(Hahn et al., 1996). A low level of TβRII protein identifies a
cohort of women with mammary epithelial hyperplasia at
increased risk for development of breast cancer (Gobbi et al.,
1999). Other studies have suggested that an excess of
endogenous TGFβ can prevent tumor development. For exam-
ple, MMTV/TGFβ1 mice are resistant to DMBA-induced mam-
mary tumors, and MMTV/TGFα × MMTV/TGFβ1 bigenic mice
fail to develop mammary carcinomas seen in MMTV/TGFα
mice (Pierce et al., 1995). Mice overexpressing active TGFβ1
under the control of the K14 promoter are relatively protected
from skin tumors induced by chemical carcinogens (Cui et al.,
1996).This is consistent with the ability of TGFβ to maintain tis-
sue architecture, inhibit genomic instability, and induce replica-
tive senescence and apoptosis in nontransformed cells and/or
tissues (illustrated in Figure 1). These studies support the
tumor-suppressive role of endogenous TGFβ. To date, howev-
er, administration of exogenous TGFβ has not been reported to
prevent cancer formation.
Most cancers retain TGFβ receptors but attenuate TGFβ-
mediated antimitogenic effects. In contrast to colorectal and
pancreatic cancers, Smad2 and Smad4 mutations are rare in
other tumor types. Furthermore, the tumors that develop in
TGFβ haploid mice do not lose the second TGFβ allele and, in
fact, express higher levels of TGFβ protein than TGFβ+/+ tumors
(Tang et al., 1998). In addition, many tumor cells exhibit
increased invasiveness in response to TGFβ (reviewed in
Dumont and Arteaga, 2000). TGFβ can also induce an epithe-
lial-to-mesenchymal transition (EMT) in tumor and nontumori-
genic immortalized cells (Miettinen et al., 1994). Reexpression
of TβRII in colon cancer cells with low invasive potential
restores tumor cells invasiveness (Oft et al., 1998), and induc-
tion of TGFβ1 in papillomas induces metastatic carcinomas
(Weeks et al., 2001). Patients whose pancreatic cancers over-
expressed TβRII mRNA had a shorter survival than patients
bearing cancers with lower TβRII mRNA (Wagner et al., 1999).
Forced expression of active Smad2 in squamous cancer cells
results in enhanced tumor cell motility and metastatic dissemi-
nation (Oft et al., 2002). Further, introduction of dominant nega-
tive TβRII into a variety of metastatic carcinoma cells prevents
conversion to a mesenchymal phenotype and inhibits motility,
tumorigenicity, and metastases (reviewed in Dumont and
Arteaga, 2000). These data suggest that, although partial loss
of TGFβ signals is permissive for tumor development, there is
no selective pressure in cancer cells to lose TGFβ signaling
completely. Secondly, some residual TGFβmight be required for
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tumor maintenance and, in fact, may select for more metastatic
cancers. Perhaps the best demonstration of this hypothesis was
provided by Cui et al. (1996). Mice overexpressing active TGFβ1
in keratinocytes develop fewer benign papillomas than controls.
However, the transgenic tumors rapidly acquire a spindle cell
phenotype, overexpress TGFβ3, and metastasize (Cui et al.,
1996). Parenthetically, colon cancers with microsatellite instabil-
ity and inactivating mutations of the TGFBR2 gene exhibit favor-
able survival compared to TβRII-positive colon cancers
(Watanabe et al., 2001), suggesting that loss of TGFβ signaling
may limit systemic metastases.
There is also abundant evidence to support that excess
production and/or activation of TGFβ in tumors can foster can-
cer progression by paracrine mechanisms (Figure 1). These
include an increase in tumor neoangiogenesis and
extracellular matrix production, upregulation of peritumor met-
alloproteases, and the subversion of immune surveillance
mechanisms (Derynck et al., 2001). Overexpression of TGFβ
ligands has been reported in most tumor types (reviewed in
Wojtowicz-Praga, 2003). Most of these reports are immuno-
histochemical studies utilizing antibodies that do not discrimi-
nate between active and latent TGFβ. Although some studies
claim excess activation of TGFβ in cancer compared to nontu-
mor tissues, this can only be confirmed by use of TGFβ
inhibitors and assessment of their effects against TGFβ-
expressing tumors. Nonetheless, elevated levels of TGFβ in
tumor tissues correlate with markers of a more metastatic
phenotype and/or poor patient outcome (reviewed in Dumont
and Arteaga, 2000). In glioblastomas, TGFβ2 overexpression
has been associated with immunosuppression in patients
(Kuppner et al., 1988). Elevated levels of plasma TGFβ are
detected in patients with cancer, and these can predict for
early metastatic recurrences (Tsushima et al., 2001).
Is there a role for TGFβ in cancer prevention/treatment?
A recent report indicates that a T29→C polymorphism in the
TGFB1 gene results in increased serum levels of TGFβ1 and is
associated with a reduced risk of breast cancer (Ziv et al.,
2001). These results plus the ability of TGFβ to inhibit epithelial
proliferation and prevent tumor development in transgenic mice
suggest that exogenous TGFβ can be utilized for cancer pre-
vention. However, the demonstrations that TGFβ can induce
signaling pathways associated with transformations like Erk,
p38 MAPK, PI3K/Akt, JNK, and the Rho family of GTPases sug-
gest that exogenous TGFβ might be counterproductive as a
therapeutic strategy. Furthermore, overexpression of Ras in
nontumor epithelial cells synergizes with TGFβ in the induction
of epithelial plasticity and enhanced cell survival (Janda et al.,
2002; Oft et al., 1996), suggesting that some oncogenes can
potentially synergize with TGFβ in early phases of transforma-
tion. Further, MMTV/neu × TGFβ1 and MMTV/PyV mT × TGFβ1
bigenic mice develop mammary tumors with similar latency to
MMTV/neu and MMTV/PyV mT mice, respectively (C.L.A.,
unpublished data), implying that some oncogenes, unlike
TGFα, are dominant over TGFβ.
Exogenous TGFβ may also have some negative conse-
quences in patients with cancer. For example, administration of
recombinant TGFβ1 to mice bearing MDA-231 xenografts does
not inhibit tumor growth, but induces cachexia and generalized
interstitial fibrosis in the spleen (Zugmaier et al., 1991). Daily
injections of recombinant TGFβ1 facilitate tumor formation by
estrogen-dependent MCF-7 human breast cancer cells in the
absence of estrogen supplementation (Arteaga et al., 1993a).
These data suggest the possibility of significant toxicities and a
potential tumor-permissive role for treatment with this cytokine.
Thus, the use of TGFβ as a cancer prevention or treatment
strategy is highly questionable.
Blockade of TGFβ: Cellular mechanisms of action
The improved outcome of patients bearing cancers with
TGFBR2 mutations suggests an argument in favor of therapeutic
blockade of autocrine TGFβ signaling. An additional argument is
inferred by the paracrine effects of tumor TGFβs on angiogene-
sis, stroma formation and remodeling, and immunosuppression.
Thus, by blocking TGFβ function, one can interrupt multiple
events important for tumor maintenance. Indeed, preclinical
studies have proved the principle that inhibition of TGFβ affects
these tumor-permissive autocrine and paracrine mechanisms.
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Figure 1. Diagram of tumor suppressor and
tumor promoting effects of TGFβ
As a result of oncogenic stimuli or other
unknown mechanisms, human cancers attenu-
ate TGFβ-induced suppression but exploit TGFβ-
mediated autocrine and paracrine
mechanisms conducive to tumor progression. It
is likely that in many cancers, both situations are
operative, i.e., TGFβ may still attenuate prolifer-
ation while inducing cellular events associated
with metastatic dissemination. There is experi-
mental evidence that (1) loss of TGFβ signaling
will increase the risk of cancer development
(tumor suppressor function), and (2) inhibition of
autocrine/paracrine TGFβ in tumors will delay
metastatic progression (tumor promoter func-
tion). In the natural progression of different can-
cers from preneoplasia to advanced
metastatic states, the timing at which the role of
TGFβ switches from tumor suppressor to promot-
er is unclear.
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In MMTV/PyV mT transgenic mice, blockade of TGFβ with
soluble TβRII:Fc increases apoptosis in primary mammary
tumors and inhibits tumor cell motility, intravasation, and metas-
tases (Muraoka et al., 2002). In this report, treatment with
sTβRII:Fc inhibited Akt activity in tumors. TGFβ antibodies also
inhibit PI3K/Akt activity in 4T1 and EMT-6 mammary cancer
cells (Bakin et al., 2000). In transformed cells, TGFβ-induced
survival is associated with Akt-induced phosphorylation of
FKHRL1, and this effect is blocked by expression of kinase-
dead Akt (Shin et al., 2001). These data imply that TGFβ antag-
onists may need to inhibit PI3K/Akt to induce an antitumor
effect. In a recent study, reconstitution of TβRI signaling in MDA-
231 human breast cancer cells expressing dominant negative
TβRII restored motility and enhanced survival while increasing
Akt and ERK activities but not Smad2 phosphorylation (Dumont
et al., 2003). This report suggests that, in some metastatic can-
cer cells, the tumor progressive effects of TGFβ occur at a low
threshold of receptor activation and may use Smad-indepen-
dent mechanisms. The clinical implications of these data are
that (1) TGFβ receptor-positive, Smad mutant cancers may still
use TGFβ for tumor progression, and (2) therapeutically, a more
complete inhibition of TGFβ signaling might be required to block
the tumor-permissive effects of TGFβ.
A monoclonal pan-TGFβ neutralizing antibody suppresses
the growth of TGFβ1-overexpressing renal cancer xenografts
while abrogating factor VIII expression (Ananth et al., 1999),
suggesting an antiangiogenic effect. Cancer cells stably trans-
fected with soluble forms of TβRII or TβRIII exhibit reduced
tumorigenicity and microvessel density compared to control
tumors (Bandyopadhyay et al., 1999; Rowland-Goldsmith et al.,
2001). There is also evidence that overexpression of sTβRII:Fc
in thymoma cells can prevent the progression of unmodified thy-
moma cells when injected near the primary tumor inoculation
site. Stable transduction of breast and glioma tumor cells with
antisense TGFβ1 and TGFβ2 retroviruses, respectively,
restores their immunogenicity when injected into immunocom-
petent mice which, in turn, induces partial rejection of unmodi-
fied established tumors (reviewed in Dumont and Arteaga,
2000). These examples suggest that presence of TGFβ neutral-
izing activity within the tumor milieu can restore tumor-specific
cellular immunity and mediate tumor rejection. Along those
lines, transgenic mice expressing a dominant negative TβRII
under the control of a T cell specific promoter eradicate tumors
when challenged with live tumor cells (Gorelik and Flavell,
2001). Finally, the 2G7 pan-TGFβ neutralizing IgG2 suppresses
the establishment of MDA-231 tumors and lung metastases in
athymic mice and prevents the inhibition of host NK cell function
induced by tumor inoculation (Arteaga et al., 1993b). The anti-
body had no effect against MDA-231 cells in vitro, nor did it
inhibit primary and metastatic tumors in NK-deficient mice, sug-
gesting that antibody-mediated TGFβ blockade is effective in
disrupting tumor-host immunosuppressive interactions that are
essential for cancer progression.
Blockade of TGFβ in normal cells may induce side effects in
the tumor host that can be anticipated. Complete loss of TGFβ
in mice is associated with a severe inflammatory response.
Complete elimination of TGFβ function in T cells leads to
autoimmune disorders (Gorelik and Flavell, 2001). A recent
experiment, however, suggests that TGFβ antagonists might be
well tolerated. Mice expressing soluble TβRII under the regula-
tion of the MMTV/LTR promoter exhibit high levels of the TGFβ
antagonist in the circulation without the severe inflammatory
phenotype of TGFβ null mice.The circulating levels of sTβRII:Fc
were sufficient to inhibit tumor metastases in this model. Mild
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Table 1. Current status of development of TGFβ inhibitors
Agent Class Development stage Source References
CAT-192 Humanized TGFβ1 mAb Phase II (diffuse systemic sclerosis) Genzyme/CAT
CAT-152 Humanized TGFβ2 mAb Phase III (glaucoma) Genzyme/CAT Siriwardena et al., 2002
1D11 TGFβ1, 2, 3 mAb Preclinical Genzyme/CAT Ananth et al., 1999
2G7 TGFβ1, 2, 3 monoclonal IgG2 Preclinical Genentech Arteaga et al., 1993b
sTβRII:Fc RII/Fc hu IgG1 fusion protein Preclinical Biogen Muraoka et al., 2002
Betaglycan Recombinant soluble TβRIII Preclinical Bandyopadhyay et al., 1999, 2002
SB-431542 Small molecule TβRI kinase inhibitor Preclinical GlaxoSmithKline Laping et al., 2002
NPC 30345 Small molecule TβRI kinase inhibitor Preclinical Scios, Inc.
LY364947 Small molecule TβRI kinase inhibitor Preclinical Lilly Research Sawyer et al., 2003
AP-12009 Antisense TGFβ2 Phase I/II (glioblastoma) Antisense Pharma Marzo et al., 1997
Figure 2. Sites of action of TGFβ antagonists currently in development
Each class of inhibitors is marked with Ø. Smad7 is a negative regulator of
TGFβ signaling that has also been proposed as a therapeutic approach.
There are no reports of ligand-blocking TGFβ receptor antibodies in clinical
development.
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lymphocytic infiltration in lungs, kidneys, and pancreas were
observed (Yang et al., 2002). It is likely that the severe inflam-
matory and autoimmune phenotype observed in genetically
engineered mice reflects the complete loss of TGFβ function, a
level of inhibition that is unlikely to be achieved with exogenous
inhibitors. Because of the stabilizing effect of TGFβ on blood
vessels, TGFβ antagonists may affect wound healing.
Interestingly, administration of a TGFβ2 antibody via subcon-
junctival injections immediately before and after trabeculectomy
for glaucoma was not associated with impaired healing
(Siriwardena et al., 2002).
Perhaps the greatest risk of TGFβ antagonists is the poten-
tial acceleration of preneoplastic lesions or cancers in which
TGFβ still exerts growth restraint (Figure 1). In support of this
possibility, expression of an antisense TGFβ1 expression vector
in well-differentiated colon cancer cells enhances their tumori-
genicity in nude mice (Wu et al., 1993). In other reports, admin-
istration of a TGFβ neutralizing antibody or expression of
soluble TβRII results in enhanced angiogenesis and/or larger
primary tumor size (Gohongi et al., 1999). The possibility that
blockade of TGFβ with exogenous antagonists can accelerate
transformation, tumor onset, and/or cancer progression
requires rigorous investigation in preclinical models.
Clinical development of TGFβ inhibitors
The development of anticancer molecular therapeutics
requires the identification of a measurable molecular target
that can aid in the selection of appropriate patients for clinical
trials. This issue is not clear with TGFβ antagonists, since the
target network includes three ubiquitous ligands in an
unknown state of activation and receptors present in both
tumor and nontumor cells. The ubiquituous expression of all
three TGFβ ligands in human tumors, plus the inability to
accurately ascertain their level of a possibly dynamic and spa-
tially regulated activation in situ, argue against TGFβ expres-
sion being such predictive marker for patient selection. One
possible exception are patients with glioblastoma in whom
TGFβ2 overexpression is associated with immune suppres-
sion. Several arguments suggest that expression of TβRII
might be a good marker to use. First, most tumors retain
TβRII. Second, interference of TβRII function in mesenchymal-
ly differentiated carcinomas has been shown to reverse their
mesenchymal phenotype and/or inhibit metastases. Third,
expression of TβRII in tumors has been associated with short-
er patient survival (Wagner et al., 1999; Watanabe et al.,
2001). Therefore, we propose that patients with poorly differ-
entiated carcinomas (i.e., with mesenchymal features) that
express TβRII should be appropriate candidates for the testing
of TGFβ antagonists. In these tumors, TGFβ blockade could
potentially inhibit both autocrine TGFβ signaling in tumor cells
and the paracrine/endocrine effects of TGFβ.
Several approaches to block TGFβ function are being pur-
sued (Table 1 and Figure 2). One approach is aimed at blocking
ligand access to TGFβ receptors. Two humanized monoclonal
antibodies: CAT-192, specific to TGFβ1, and CAT-152, against
TGFβ2, are in early clinical development. The expression of
multiple TGFβ isoforms in tumors suggests that a pan-TGFβ
antibody might be more effective than isoform-specific antibod-
ies.Two pan-TGFβmonoclonal antibodies, 1D11 and 2G7, have
been reported. One approach to prevent binding of TGFβ lig-
ands is the use of recombinant fusion proteins containing the
ectodomains of TβRII and TβRIII. Soluble TβRII:Fc has shown
efficacy in fibrosis and metastases models. Human recombi-
nant TβRIII has shown antimetastatic and antiendothelial cell
activity. One attractive feature of recombinant betaglycan over
sTβRII is its greater affinity for TGFβ2.
A second group of strategies is aimed at directly blocking
the receptors’ catalytic activity. SBI-14352, NPC 30345, and
LY364947 are ATP competitive inhibitors of the ATP binding site
of the TβRI kinase. This approach spares the TβRII kinase and,
therefore, may not inhibit TGFβ function completely. If complete
inhibition of TGFβ was required for antitumor action, this selec-
tivity could compromise anticancer activity but at the same time
ameliorate potential toxicities. These two possibilities are theo-
retical, since there are no known TβRII functions that do not
require TβRI. Nonetheless, the development of bifunctional
receptor inhibitors should help in resolving these questions.
Vectors encoding the inhibitory Smad, Smad7, have been used
to bind TβRI and interfere with Smad2/3 phosphorylation
(Nakao et al., 1997). This strategy should be viewed with cau-
tion in that it will not block Smad-independent TGFβ-induced
responses conducive to tumor progression. Indeed, Smad7
mRNA is overexpressed in pancreatic cancers, and its forced
expression in pancreatic cancer cells results in loss of TGFβ-
mediated growth inhibition but facilitates anchorage-indepen-
dent growth and tumorigenicity (Kleeff et al., 1999). Moreover,
blockade of Smad4 has been shown to facilitate TGFβ-depen-
dent and -independent activation of Erk in squamous cancer
cells and promote their motility and transmesenchymal differen-
tiation (Iglesias et al., 2000), suggesting that postreceptor inter-
ference of Smads as an anticancer strategy may be
conceptually weak. The TGFβ antagonists discussed above are
summarized in Table 1.
Conclusions
There is preponderant experimental evidence to suggest that
TGFβ signaling can foster tumor-host interactions that indi-
rectly support neoplastic cell viability and progression. Further
evidence also suggests that autocrine TGFβ signaling is oper-
ative in some tumor cells and can also contribute to tumor
invasion, survival, and metastases. These multiple tumor-per-
missive effects of TGFβ provide for a therapeutic opportunity
in that by blocking this signaling network, one can interrupt
multiple autocrine and paracrine mechanisms that are essen-
tial for tumor maintenance. Many questions exist about the
viability of this treatment strategy as it applies to patient and
tumor selection, molecular predictors of response to therapy,
biochemical surrogates for determination of optimal dosing,
potential toxicities, and the possible inclusion of inhibitors of
TGFβ activation to the strategies summarized above.
Nonetheless, the plethora of TGFβ antagonists in develop-
ment suggest that these questions will be addressed in the
near future.
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